logo-loader

Silence Therapeutics to be a clinical-stage company by year-end

Published: 19:50 07 Mar 2018 AEDT

Torsten Hoffmann, chief operating officer at Silence Therapeutics PLC (LON:SLN) chats to Proactive's Andrew Scott following the release of their preliminary 2017 results.

Hoffmann says the big focus for them is working towards filing their first GalNAc-siRNA CTA (clinical trial authorisation) for the treatment of liver-related iron overload disorders by the end of 2018.

Five senior managers have recently been recruited to spearhead the clinical drive.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 21 minutes ago